Sanofi (SNY) Assets (2009 - 2026)
Sanofi's (SNY) quarterly Assets came in at $150.0 billion in Q2 2026, up 6.06% year-over-year from $141.4 billion in Q2 2025, and little changed quarter-over-quarter from $149.9 billion in Q1 2026.
Analysis
Sanofi (SNY) Assets (2009 - 2026) Analysis & Trends
Sanofi has disclosed Assets across 18 years of filings, most recently posting $150.0 billion for Q2 2026.
- In Q2 2026, Assets rose 6.06% year-over-year to $150.0 billion; the TTM figure through Jun 2026 stood at $150.0 billion (up 6.06% YoY), while the FY2025 annual figure was $147.6 billion, up 2.7% from the prior year.
- Assets came in at $150.0 billion for Q2 2026 at Sanofi, roughly flat from $149.9 billion in the prior quarter.
- In the past five years, Assets ranged from a high of $151.7 billion in Q3 2025 to a low of $129.3 billion in Q4 2022.
- Average Assets over 5 years is $141.1 billion, with a median of $140.6 billion recorded in 2025.
- Year-over-year, Assets retreated 6.01% in 2022 and grew 8.04% in 2026.
- Over 5 years, Assets stood at $129.3 billion in 2022, then climbed by 5.24% to $136.1 billion in 2023, then climbed by 4.29% to $141.9 billion in 2024, then grew by 4.02% to $147.6 billion in 2025, then climbed by 1.63% to $150.0 billion in 2026.
- Per Business Quant data, the three most recent Assets figures were $150.0 billion in Q2 2026, $149.9 billion in Q1 2026, and $147.6 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.60 Bn | 621.84 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 447.11 Bn | 440.55 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 358.25 Bn | 351.11 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 267.57 Bn | 259.88 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Pfizer | 156.64 Bn | 144.94 Bn | 10.94 Bn | 201.13 Bn |
| 6 | Sanofi | 52.20 Bn | 44.82 Bn | 10.79 Bn | 150.01 Bn |
| 7 | Revolution Medicines | 42.91 Bn | 42.91 Bn | - | 4.32 Bn |
| 8 | Incyte | 24.64 Bn | 20.11 Bn | 1.57 Bn | 7.87 Bn |
| 9 | United Therapeutics | 21.56 Bn | 18.90 Bn | 683.80 Mn | 7.22 Bn |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | 5.36 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 150.01 Bn |
| Mar 31, 2026 | 149.88 Bn |
| Dec 31, 2025 | 147.61 Bn |
| Sep 30, 2025 | 151.74 Bn |
| Jun 30, 2025 | 141.45 Bn |
| Mar 31, 2025 | 138.74 Bn |
| Dec 31, 2024 | 141.91 Bn |
| Jun 30, 2024 | 139.73 Bn |
| Dec 31, 2023 | 136.07 Bn |
| Jun 30, 2023 | 136.50 Bn |
| Dec 31, 2022 | 129.29 Bn |
| Jun 30, 2022 | 130.00 Bn |
| Dec 31, 2021 | 137.55 Bn |
| Jun 30, 2021 | 135.26 Bn |
| Dec 31, 2020 | 136.41 Bn |
| Jun 30, 2020 | 127.57 Bn |
| Dec 31, 2019 | 1.75 Bn |
| Jun 30, 2019 | 124.21 Bn |
| Dec 31, 2018 | 127.16 Bn |
| Sep 30, 2018 | 1.85 Bn |